Testosterone treatment not linked to prostate cancer (PCa)
Source: PLoS ONE
Curated by: Craig Hicks
June 26, 2018
Takeaway
- Testosterone treatment is not associated with a greater risk for prostate cancer (PCa) in men with low testosterone levels and normal prostate-specific antigen (PSA) levels.
Why this matters
- “Given the association between testosterone treatment and increase in PSA levels and prostate biopsy, information on the near term risk of prostate cancer among this group of men is important for clinical decision making,” say researchers.
Study design
- The researchers studied male veterans with low testosterone and recent PSA testing (n=147,593; 58,617 treated with testosterone; age range, 40-89 years).
- Primary and secondary outcomes: histologically confirmed incident aggressive PCa and any PCa.
- Funding: National Institute on Aging; Department of Veterans Affairs.
Key results
- There were 313 diagnoses of aggressive PCa:
- 190 among untreated men: incidence rate (IR), 0.57 per 1000 person-years; and
- 123 among treated men: IR, 0.58 per 1000 person-years.
- Testosterone treatment was not associated with incident aggressive PCa (HR, 0.89) or any PCa (HR, 0.90), after adjusting for age, race, hospitalization during the year before cohort entry, geography, BMI, and medical comorbidities.
Limitations
- Risks and benefits of testosterone treatment can be fully addressed only by large, long-term randomized controlled trials.